Kiropoulos Litza, Dang Phuong Linh, Rozenblat Vanja
Mood and Anxiety Disorders Lab, Melbourne School of Psychological Sciences, The University of Melbourne, Victoria, Australia.
Royal Melbourne Hospital, Melbourne, VIC, Australia.
BMC Cancer. 2025 Jul 14;25(1):1170. doi: 10.1186/s12885-025-14569-z.
Mindfulness-based interventions have provided consistent benefits for the physical and emotional wellbeing of cancer patients. However, their feasibility has not been examined in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), particularly in the post-transplant phase. The aim of this study was to examine the feasibility and acceptability of a six-week group-based mindfulness intervention and to examine whether this intervention improves psychological adjustment to cancer in haematological cancer patients who have undergone an allogeneic HSCT.
Twenty eligible participants were recruited from the Haematology and Bone Marrow Transplant Unit at the Royal Melbourne Hospital, Melbourne, Victoria. Primary outcomes were the feasibility and acceptability of the mindfulness intervention. Secondary outcomes include examination of depression, anxiety, quality of life, psychological adjustment to cancer, mindfulness skills, emotion regulation strategies, and cancer-related pain, fatigue, and physical functioning. Evaluation of treatment was examined using a treatment evaluation questionnaire and qualitative interview. This trial has been registered on 3/10/2024 ( https://doi.org/10.1186/ISRCTN61068398 ) and is complete.
Following treatment, participants (n = 13) reported significant decreases (with large effect sizes, r =.78 to 0.88) in the levels of anxious preoccupation in response to cancer, physical functioning, the non-judging facet of mindfulness, and a significant increase in perceived functional wellbeing. Qualitative analysis indicated that participants valued the social support element of the group format and for the intervention to be offered before and after the allogeneic HSCT procedure.
This study found that a tailored six-week mindfulness group intervention was feasible and accepted by haematological cancer patients post-HSCT and that participants reported improvements in factors such as functional wellbeing and reductions in anxious preoccupation.
基于正念的干预措施已为癌症患者的身心健康带来了持续的益处。然而，其在接受异基因造血干细胞移植（HSCT）的患者中的可行性尚未得到研究，尤其是在移植后阶段。本研究的目的是检验一项为期六周的基于团体的正念干预的可行性和可接受性，并检验该干预是否能改善接受异基因HSCT的血液系统癌症患者对癌症的心理调适。
从维多利亚州墨尔本皇家墨尔本医院的血液学和骨髓移植科招募了20名符合条件的参与者。主要结局是正念干预的可行性和可接受性。次要结局包括对抑郁、焦虑、生活质量、对癌症的心理调适、正念技能、情绪调节策略以及与癌症相关的疼痛、疲劳和身体功能的检查。使用治疗评估问卷和定性访谈对治疗进行评估。该试验已于2024年10月3日注册（https://doi.org/10.1186/ISRCTN61068398）且已完成。
治疗后，参与者（n = 13）报告称，对癌症的焦虑关注水平、身体功能、正念的非评判方面有显著下降（效应量较大，r = 0.78至0.88），且感知到的功能幸福感显著增加。定性分析表明，参与者重视团体形式的社会支持元素以及在异基因HSCT程序前后提供干预。
本研究发现，针对HSCT后的血液系统癌症患者量身定制的为期六周的正念团体干预是可行的且被接受，参与者报告在功能幸福感等因素方面有所改善，对癌症的焦虑关注有所减少。
